News | February 05, 2025
Pfizer reports 2024 revenues 7% higher at $63.6 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
These solutions combine scientifically or clinically validated, regulatory-approved probiotic strains with precise dosing
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
Q3 FY25 revenue up 24% to Rs 3,230 crore
PAT after MI is Rs. 41 crore which is 162% increase
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
Subscribe To Our Newsletter & Stay Updated
